News
Video
Author(s):
Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies
Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes